Study wrapper · #315
Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway.
Editor's note
A mouse study, plus supporting human lung-cell work, reporting that GHK-Cu, injected intraperitoneally, was associated with reduced cigarette-smoke-induced emphysema, less airway inflammation and lower oxidative stress over 12 weeks of smoke exposure. Researchers proposed an anti-inflammatory mechanism via reduced NF-kB signalling and an antioxidant mechanism via increased Nrf2, alongside a partial rebalancing of the MMP-9/TIMP-1 enzymes involved in lung-tissue breakdown. These are preclinical findings, from a rodent emphysema model with A549 cell experiments, and human data are needed before clinical conclusions can be drawn. It aligns with a companion line of GHK-Cu smoke-injury research and adds coherence at the mechanism level, but the same caveats apply: the delivery route (injection in mice) and doses do not translate directly to human use, and no clinical respiratory endpoint in people was measured. For GHK-Cu readers it is a consistent preclinical signal in lung-injury models, worth noting, not clinically actionable, and not evidence for systemic use in humans.
Plain-language abstract
This study tested whether the copper peptide GHK-Cu could reduce lung damage from cigarette smoke, using mice and some human lung-cell experiments. Researchers exposed mice to cigarette smoke for 12 weeks to bring on emphysema, the lung damage seen in COPD, and gave some of them GHK-Cu by injection into the abdomen every other day at several doses. Compared with untreated smoke-exposed mice, GHK-Cu-treated mice showed less emphysema-type damage and less inflammation and oxidative stress in the lungs. The researchers linked this to two internal switches: GHK-Cu appeared to turn down an inflammation pathway (NF-kB) and turn up an antioxidant defence pathway (Nrf2). It also partly restored the balance of enzymes that build up and break down lung tissue. In human lung cells exposed to smoke extract, GHK-Cu similarly reduced signs of oxidative stress. These are cell and mouse findings using injected peptide, and human studies would be needed before any conclusions for people with COPD.